申请人:Pierre Fabre Medicament
公开号:US05591743A1
公开(公告)日:1997-01-07
A 3,5-dioxo-(2H,4H)-1,2,4-triazine compounds of formula I ##STR1## in which: R.sub.1 and R.sub.2, which are identical or different, represent hydrogen or C.sub.1 -C.sub.6 alkyl, n is 2 to 6, inclusive, A represents aryl piperazino II ##STR2## the Ar grouping representing phenyl, naphthyl, pyrimidyl, or pyridyl, unsubstituted or substituted by C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, hydroxy, trifluoromethyl, or halogen, or III benzodioxanyl-methyl-amino or pyridodioxanyl-methyl-amino ##STR3## in which R represents hydrogen or C.sub.1 -C.sub.3 alkyl and X represents a nitrogen or carbon atom, therapeutically-acceptable salts and enantiomers thereof, pharmaceutical compositions thereof, and method for treatment of diseases requiring a 5HT.sub.1A receptor agonist therewith.
化学式为I的3,5-二氧代-(2H,4H)-1,2,4-三嗪类化合物:##STR1## 其中:R.sub.1和R.sub.2,相同或不同,表示氢或C.sub.1-C.sub.6烷基,n为2至6,包括在内,A表示芳基哌嗪II:##STR2## 其中,Ar基团表示苯基、萘基、嘧啶基或吡啶基,未取代或取代为C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷氧基、羟基、三氟甲基或卤素,或III苯并二氧杂环基甲基氨基或吡啶二氧杂环基甲基氨基:##STR3## 其中,R表示氢或C.sub.1-C.sub.3烷基,X表示氮或碳原子,其治疗上可接受的盐和对映异构体,其制药组合物,以及使用其作为5HT.sub.1A受体激动剂治疗需要该类药物治疗的疾病的方法。